This Biotech's on the NuPathe to Success
By Sean Williams | More Articles | Save For Later
January 18, 2013 | Comments (0)
Sentiment: Strong Buy
PATH was $9. This is Cheap. bought
at work catching up bought today
loaded up .
"Considering that NuPathe was valued around $9 per share when Zecuity first went in front of the FDA, I'm hopeful it will head higher from here, but I'm anxiously waiting to hear who'll be its commercial marketing partner"
extreme undervalued. Partner Fast